相关实验视频

Updated: Sep 11, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

阿莱克提尼布在布里加替尼布后对高级ALK+非小细胞肺癌的疗效 (BrigALK2-GFPC 02-2019研究)

Renaud Descourt¹, Florian Guisier², Maurice Pérol³

¹Hopital La Cavale Blanche, CHU Brest, Brest, France.

Lung Cancer (Auckland, N.Z.)

|August 18, 2025

概括

在晚期阿纳普拉斯性淋巴瘤激酶阳性非小细胞肺癌患者治疗布里加替尼布后,阿莱克提尼布的疗效有限. 然而,它可能是一个可行的选择,特别是如果布里加替尼因毒性而停止使用.

科学领域:

在瘤学瘤学.
药理学药理学是指药理学的学科.

背景情况:

布里加替尼布和阿莱克提尼布是治疗ALK阳性晚期非小细胞肺癌 (NSCLC) 的有效阿纳普拉斯性淋巴瘤激酶抑制剂 (ALKi).
在布里加替尼治疗失败后,对alectinib的疗效存在有限的现实世界数据.

研究的目的:

评估alectinib在先进ALK阳性NSCLC患者的现实疗效,这些患者先前接受过布里加替尼.

主要方法:

在早期准入计划 (EAP) 中,在布里加替尼布之后接受alectinib治疗的患者的回顾性分析.
主要终点:由当地调查人员评估的alectinib中位数无进展生存期 (mPFS).

主要成果:

在接受alectinib后brigatinib的30名患者中,mPFS在brigatinib后立即给予时为4.8个月.
接受alectinib立即后brigatinib的患者的平均整体存活期 (mOS) 为27个月.
阿莱克提尼布的活性有限,尤其是在布里格提尼布和阿莱克提尼布之间给予其他治疗时.

结论:

在先进的ALK阳性NSCLC中布里加替尼布失败后,阿莱克提尼布显示出有限的整体活性.
阿列克提尼布仍然是一个潜在的治疗选择,特别是在因毒性而停止布里加替尼布时.

关键词:

ALK+非小细胞肺癌是一种非小细胞肺癌.亚莱克提尼布 (alectinib) 是一种药物.布里加丁尼布 (Brigatinib) 的使用情况管理的管理管理的管理.

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...